CLAIMS

We Claim:

1. A compound of formula I:



I

in which:

n is selected from 0, 1 and 2;

m is selected from 0, 1 and 2;

X is selected from O and NR_6; wherein R_6 is C_{1-4}alkyl;

Y_1 is selected from N and CR_7; wherein R_7 is selected from hydrogen and C_{1-4}alkyl;

R_1 is hydrogen;

R_2 is selected from hydrogen and halo;

R_3 is selected from $-CH_2CH_2R_{8b}$ and $-CR_{8a}=CR_{8a}R_{8b}$; wherein each R_{8a} is independently selected from hydrogen, fluoro and C_{1-4}alkyl; and R_{8b} is selected from $-C(O)OR_{9a}$, $-C(O)NR_{9a}R_{9b}$, $-C(O)NHOR_{9a}$, $-C(O)X_2R_{9a}$ and a 5-6 member heteroaryl selected from:

RECTIFIED SHEET (RULE 91) ISA/EP



wherein the dotted line indicates the point of attachment with $-CH_2CH_2$ or $-CR_{8a}=CR_{8a}$ of R_3; wherein X_2 is C_{1-4}alkylene; R_{9a} and R_{9b} are independently selected from hydrogen, C_{1-4}alkyl, hydroxy-substituted-C_{1-4}alkyl, halo-substituted-C_{1-4}alkyl and $-X_4R_{10}$; wherein X_4 is selected from a bond and C_{1-3}alkylene; and R_{10} is a 4-6 member saturated ring containing 1 to 3 atoms independently selected from O, N and S; wherein said heteroaryl of R_{8b} is unsubstituted or substituted with 1 to 3 groups independently selected from C_{1-4}alkyl and C_{3-8}cycloalkyl;

R_4 is selected from hydrogen, C_{1-4}alkyl, halo and C_{1-3}alkoxy;

R_5 is selected from C_{6-10}aryl and a 5-6 member heteroaryl selected from:



[0001] wherein the dotted line indicates the point of attachment with the benzothiophene core; wherein said C_{6-10}aryl or heteroaryl of R_5 is substituted with 1 to 3 group selected from $-X_3$-R_{5a} and R_{5a}; wherein X_3 is methylene; R_{5a} is selected from hydroxy, amino, C_{1-4}alkyl, halo, nitro, cyano, halo-substituted-C_{1-4}alkyl, cyano-substituted-C_{1-4}alkyl, hydroxy-substituted-C_{1-4}alkyl, halo-substituted-C_{1-4}alkoxy, C_{1-4}alkoxy, $-SF_5$, $-NR_{11a}R_{11b}$, $-C(O)R_{11a}$, C_{3-8}cycloalkyl and a 4-7 member saturated, unsaturated or partially saturated ring containing one to 4 heteroatoms or groups selected

RECTIFIED SHEET (RULE 91) ISA/EP

from O, NH, C(O) and $S(O)_{0-2}$; wherein R_{11a} and R_{11b} are independently selected from hydrogen and C_{1-4}alkyl; or R_{11a} and R_{11b} together with the nitrogen to which they are both attached form a 4 to 7 member saturated ring containing one other heteroatom or group selected from O, NH, and $S(O)_{0-2}$; wherein said 4-7 member ring of R_{5a} can be unsubstituted or substituted with C_{1-4}alkyl; or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 of formula Ia:



Ia

in which:

n is selected from 0, 1 and 2;

m is selected from 0, 1 and 2;

Y_1 is selected from N and CR_7; wherein R_7 is selected from hydrogen and C_{1-4}alkyl;

R_1 is hydrogen;

R_2 is selected from hydrogen and halo;

R_3 is selected from $-CH_2CH_2R_{8b}$ and $-CR_{8a}=CR_{8a}R_{8b}$; wherein each R_{8a} is independently selected from hydrogen and C_{1-4}alkyl; and R_{8b} is selected from $-C(O)OR_{9a}$, $-C(O)NR_{9a}R_{9b}$, $-C(O)NHOR_{9a}$, $-C(O)X_2R_{9a}$, tetrazolyl, 1,3,4-oxadiazolyl, 4H-1,2,4-triazolyl, 5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl, 2-oxo-pyrimidinyl and imidazolyl; wherein X_2 is C_{1-4}alkylene; R_{9a} and R_{9b} are independently selected from hydrogen, C_{1-4}alkyl, hydroxy-substituted-C_{1-4}alkyl, halo-substituted-C_{1-4}alkyl and $-X_4R_{10}$; wherein X_4 is selected from a bond and C_{1-3}alkylene; and R_{10} is a 4-6 member saturated ring containing 1 to 3 atoms independently selected from O, N and S; wherein said tetrazolyl, 1,3,4-oxadiazolyl, 4H-1,2,4-triazolyl, 2-oxo-pyrimidinyl or imidazolyl of R_{8b} is unsubstituted or substituted with 1 to 3 groups independently selected from C_{1-4}alkyl and C_{3-8}cycloalkyl;

RECTIFIED SHEET (RULE 91) ISA/EP

R_4 is selected from hydrogen and C_{1-4}alkyl; and each

R_{5a} is independently selected from hydroxy, C_{1-4}alkyl, halo, nitro, cyano, halo-substituted-C_{1-4}alkyl, halo-substituted-C_{1-4}alkoxy, hydroxy-substituted-C_{1-4}alkyl, C_{1-4}alkoxy, C_{3-8}cycloalkyl, $-NR_{11a}R_{11b}$, $-C(O)R_{11a}$ and a 4-7 member saturated, unsaturated or partially saturated ring containing one to 4 heteroatoms or groups selected from O, NH, C(O) and $S(O)_{0-2}$; wherein X_2 is selected from a bond and methylene; wherein R_{11a} and R_{11b} are independently selected from hydrogen and C_{1-4}alkyl; wherein said 4-7 member ring of R_{5a} can be unsubstituted or substituted with C_{1-4}alkyl;

X_3 is selected from a bond and methylene; or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 in which R_3 is selected from $-CH_2CH_2R_{8b}$ and $-CR_{8a}=CR_{8a}R_{8b}$; wherein each R_{8a} is independently selected from hydrogen and C_{1-4}alkyl; and R_{8b} is selected from $-C(O)OR_{9a}$, $-C(O)NR_{9a}R_{9b}$, $-C(O)NHOR_{9a}$ and $-C(O)X_2R_{9a}$; wherein X_2 is C_{1-4}alkylene; R_{9a} and R_{9b} are independently selected from hydrogen, C_{1-4}alkyl, hydroxy-substituted-C_{1-4}alkyl, halo-substituted-C_{1-4}alkyl and morpholino-ethyl.

4. The compound of claim 3 in which R_3 is selected from $-CH_2CH_2R_{8b}$ and $-CR_{8a}=CR_{8a}R_{8b}$; wherein each R_{8a} is independently selected from hydrogen and C_{1-4}alkyl; and R_{8b} is independently selected from $-C(O)OH$, $-C(O)CH_3$, $-C(O)OCH_3$ and morpholino-ethyl.

5. The compound of claim 4, or the pharmaceutically acceptable salt thereof, selected from:



RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



6. The compound of claim 3, or the pharmaceutically acceptable salt thereof, selected from:

RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



7. The compound of claim 2 in which: R_3 is selected from $-CH_2CH_2R_{8b}$ and $-CR_{8a}=CR_{8a}R_{8b}$; wherein each R_{8a} is independently selected from hydrogen and C_{1-4}alkyl; and R_{8b} is selected from tetrazolyl, 1,3,4-oxadiazolyl, 4H-1,2,4-triazolyl, 5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl, 2-oxo-pyrimidinyl and imidazolyl; wherein said tetrazolyl, 1,3,4-oxadiazolyl, 4H-1,2,4-triazolyl, 2-oxo-pyrimidinyl or imidazolyl of R_{8b} is unsubstituted or substituted with 1 to 3 groups independently selected from C_{1-4}alkyl and C_{3-8}cycloalkyl; wherein said phenyl, pyrrolidinyl or indolizinyl of R_3 is unsubstituted or substituted with a group selected from $-C(O)OR_{13}$; wherein R_{13} is selected from hydrogen and C_{1-4}alkyl.

8. The compound of claim 7, or the pharmaceutically acceptable salt thereof, selected from:

RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



9. The compound of claim 1 or formula Ib:

RECTIFIED SHEET (RULE 91) ISA/EP



Ib

in which:

n is selected from 0, 1 and 2;

m is selected from 0, 1 and 2;

Y_1 is selected from N and CR_7; wherein R_7 is selected from hydrogen and C_{1-4}alkyl;

R_1 is hydrogen;

R_2 is selected from hydrogen and halo;

R_3 is selected from $-CH_2CH_2R_{8b}$ and $-CR_{8a}=CR_{8a}R_{8b}$; wherein each R_{8a} is independently selected from hydrogen and C_{1-4}alkyl; and R_{8b} is selected from $-C(O)OR_{9a}$, $-C(O)NR_{9a}R_{9b}$, $-C(O)NHOR_{9a}$, $-C(O)X_2R_{9a}$, tetrazolyl, 1,3,4-oxadiazolyl, 4H-1,2,4-triazolyl, 5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl, 2-oxo-pyrimidinyl and imidazolyl; wherein X_2 is C_{1-4}alkylene; R_{9a} and R_{9b} are independently selected from hydrogen, C_{1-4}alkyl, hydroxy-substituted-C_{1-4}alkyl and halo-substituted-C_{1-4}alkyl; wherein said tetrazolyl, 1,3,4-oxadiazolyl, 4H-1,2,4-triazolyl, 2-oxo-pyrimidinyl or imidazolyl of R_{8b} is unsubstituted or substituted with a group selected from C_{1-4}alkyl and C_{3-8}cycloalkyl;

R_4 is selected from hydrogen and C_{1-4}alkyl; each

R_{5a} is independently selected from hydroxy, C_{1-4}alkyl, halo, nitro, cyano, halo-substituted-C_{1-4}alkyl, halo-substituted-C_{1-4}alkoxy, hydroxy-substituted-C_{1-4}alkyl, C_{1-4}alkoxy and $-C(O)R_{11a}$; wherein R_{11a} is selected from hydrogen and C_{1-4}alkyl; and

R_6 is C_{1-4}alkyl; or a pharmaceutically acceptable salt thereof.

10. The compound of claim 9 in which R_3 is selected from $-CH_2CH_2R_{8b}$ and $-CR_{8a}=CR_{8a}R_{8b}$; wherein each R_{8a} is independently selected from hydrogen and C_{1-4}alkyl; and R_{8b} is selected from –

RECTIFIED SHEET (RULE 91) ISA/EP

$C(O)OR_{9a}$, $-C(O)NR_{9a}R_{9b}$, $-C(O)NHOR_{9a}$ and $-C(O)X_2R_{9a}$; wherein X_2 is C_{1-4}alkylene; R_{9a} and R_{9b} are independently selected from hydrogen, C_{1-4}alkyl, hydroxy-substituted-C_{1-4}alkyl and halo-substituted-C_{1-4}alkyl.

11. The compounds of claim 10, or the pharmaceutically acceptable salts thereof, selected from:



12. A compound, or the pharmaceutically acceptable salts thereof, selected from:

RECTIFIED SHEET (RULE 91) ISA/EP



RECTIFIED SHEET (RULE 91) ISA/EP



13. A pharmaceutical composition comprising a compound of claim 1 admixed with at least one pharmaceutically acceptable excipient.

14. The pharmaceutical composition of claim 13, wherein the excipient is selected from corn starch, potato starch, tapioca starch, starch paste, pre-gelatinized starch, sugars, gelatin, natural gums, synthetic gums, sodium alginate, alginic acid, tragacanth, guar gum, cellulose, ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethylcellulose, methyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, magnesium aluminum silicate, polyvinyl pyrrolidone, talc, calcium carbonate, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, agar-agar, sodium carbonate, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, clays, sodium stearate, calcium stearate, magnesium stearate, stearic acid, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, sodium lauryl sulfate, hydrogenated vegetable oil, peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, soybean oil, zinc stearate, sodium oleate, ethyl oleate, ethyl laureate, silica, and combinations thereof.

15. The pharmaceutical composition of claim 14, further comprising an additional therapeutic agent.

RECTIFIED SHEET (RULE 91) ISA/EP

16. The pharmaceutical composition of claim 15, wherein the additional therapeutic agent is selected from an anticancer compound, an analgesic, an antiemetic, an antidepressant, and an anti-inflammatory agent.

17. A method to treat cancer, comprising administering to a subject in need of such treatment an effective amount of a compound of claim 1.

18. The method of claim 17, wherein the cancer is selected from breast, ovarian, endometrial, prostate, uterine, cervical and lung cancers.

19. The method of claim 18, further comprising administering to the subject an additional therapeutic agent.

20. The method of claim 19, wherein the additional therapeutic agent comprises an anticancer drug, a pain medication, an antiemetic, an antidepressant or an anti-inflammatory agent.

RECTIFIED SHEET (RULE 91) ISA/EP

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of formula I:



I

wherein:

n is selected from 0, 1 and 2;

m is selected from 0, 1 and 2;

X is selected from O and NR_6; wherein R_6 is C_{1-4}alkyl;

Y_1 is selected from N and CR_7; wherein R_7 is selected from hydrogen and C_{1-4}alkyl;

R_1 is hydrogen;

R_2 is selected from hydrogen and halo;

R_3 is selected from $–CH_2CH_2R_{8b}$ and $–CR_{8a}=CR_{8a}R_{8b}$; wherein each R_{8a} is independently selected from hydrogen, fluoro and C_{1-4}alkyl; and R_{8b} is selected from $-C(O)OR_{9a}$, $–C(O)NR_{9a}R_{9b}$, $–C(O)NHOR_{9a}$, $-C(O)X_2R_{9a}$ and a 5-6 member heteroaryl selected from:



wherein the dotted line indicates the point of attachment with $–CH_2CH_2$ or $–CR_{8a}=CR_{8a}$ of R_3; wherein X_2 is C_{1-4}alkylene; R_{9a} and R_{9b} are independently selected from hydrogen, C_{1-4}alkyl, hydroxy-substituted-C_{1-4}alkyl, halo-substituted-C_{1-4}alkyl and $–X_4R_{10}$; wherein X_4 is selected from a bond and C_{1-3}alkylene; and R_{10} is a 4-6 member saturated ring containing 1

to 3 atoms independently selected from O, N and S; wherein said heteroaryl of R_{8b} is unsubstituted or substituted with 1 to 3 groups independently selected from C_{1-4}alkyl and C_{3-8}cycloalkyl;

R_4 is selected from hydrogen, C_{1-4}alkyl, halo and C_{1-3}alkoxy;

R_5 is selected from C_{6-10}aryl and a 5-6 member heteroaryl selected from:



;

wherein the dotted line indicates the point of attachment with the benzothiophene core; wherein said C_{6-10}aryl or heteroaryl of R_5 is substituted with 1 to 3 group selected from $–X_3-R_{5a}$ and R_{5a}; wherein X_3 is methylene; R_{5a} is selected from hydroxy, amino, C_{1-4}alkyl, halo, nitro, cyano, halo-substituted-C_{1-4}alkyl, cyano-substituted-C_{1-4}alkyl, hydroxy-substituted-C_{1-4}alkyl, halo-substituted-C_{1-4}alkoxy, C_{1-4}alkoxy, $–SF_5$, $-NR_{11a}R_{11b}$, $-C(O)R_{11a}$, C_{3-8}cycloalkyl and a 4-7 member saturated, unsaturated or partially saturated ring containing one to 4 heteroatoms or groups selected from O, NH, C(O) and $S(O)_{0-2}$; wherein R_{11a} and R_{11b} are independently selected from hydrogen and C_{1-4}alkyl; or R_{11a} and R_{11b} together with the nitrogen to which they are both attached form a 4 to 7 member saturated ring containing one other heteroatom or group selected from O, NH, and $S(O)_{0-2}$; wherein said 4-7 member ring of R_{5a} can be unsubstituted or substituted with C_{1-4}alkyl; or a pharmaceutically acceptable salt thereof.

2. A compound of formula Ia:



Ia

wherein:

n is selected from 0, 1 and 2;

m is selected from 0, 1 and 2;

Y_1 is selected from N and CR_7; wherein R_7 is selected from hydrogen and C_{1-4}alkyl;

R_1 is hydrogen;

R_2 is selected from hydrogen and halo;

R_3 is selected from $–CH_2CH_2R_{8b}$ and $–CR_{8a}=CR_{8a}R_{8b}$; wherein each R_{8a} is independently selected from hydrogen and C_{1-4}alkyl; and R_{8b} is selected from $–C(O)OR_{9a}$, $–C(O)NR_{9a}R_{9b}$, $–C(O)NHOR_{9a}$, $-C(O)X_2R_{9a}$, tetrazolyl, 1,3,4-oxadiazolyl, 4H-1,2,4-triazolyl, 5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl, 2-oxo-pyrimidinyl and imidazolyl; wherein X_2 is C_{1-4}alkylene; R_{9a} and R_{9b} are independently selected from hydrogen, C_{1-4}alkyl, hydroxy-substituted-C_{1-4}alkyl, halo-substituted-C_{1-4}alkyl and $–X_4R_{10}$; wherein X_4 is selected from a bond and C_{1-3}alkylene; and R_{10} is a 4-6 member saturated ring containing 1 to 3 atoms independently selected from O, N and S; wherein said tetrazolyl, 1,3,4-oxadiazolyl, 4H-1,2,4-triazolyl, 2-oxo-pyrimidinyl or imidazolyl of R_{8b} is unsubstituted or substituted with 1 to 3 groups independently selected from C_{1-4}alkyl and C_{3-8}cycloalkyl;

R_4 is selected from hydrogen and C_{1-4}alkyl; and each

R_{5a} is independently selected from hydroxy, C_{1-4}alkyl, halo, nitro, cyano, halo-substituted-C_{1-4}alkyl, halo-substituted-C_{1-4}alkoxy, hydroxy-substituted-C_{1-4}alkyl, C_{1-4}alkoxy, C_{3-8}cycloalkyl, $–NR_{11a}R_{11b}$, $–C(O)R_{11a}$ and a 4-7 member saturated, unsaturated or partially saturated ring containing one to 4 heteroatoms or groups selected from O, NH, C(O) and $S(O)_{0-2}$; wherein R_{11a} and R_{11b} are independently selected from hydrogen and C_{1-4}alkyl; wherein said 4-7 member ring of R_{5a} can be unsubstituted or substituted with C_{1-4}alkyl;

X_3 is selected from a bond and methylene; or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2, wherein R_3 is selected from $–CH_2CH_2R_{8b}$ and $-CR_{8a}=CR_{8a}R_{8b}$; wherein each R_{8a} is independently selected from hydrogen and C_{1-4}alkyl; and R_{8b} is selected from $–C(O)OR_{9a}$, $–C(O)NR_{9a}R_{9b}$, $–C(O)NHOR_{9a}$ and $-C(O)X_2R_{9a}$; wherein X_2 is C_{1-4}alkylene; R_{9a} and R_{9b} are independently selected from hydrogen, C_{1-4}alkyl, hydroxy-substituted-C_{1-4}alkyl, halo-substituted-C_{1-4}alkyl and morpholino-ethyl.

4. The compound of claim 3, wherein R_3 is selected from $–CH_2CH_2R_{8b}$ and $-CR_{8a}=CR_{8a}R_{8b}$; wherein each R_{8a} is independently selected from hydrogen and C_{1-4}alkyl; and R_{8b} is independently selected from –C(O)OH, $-C(O)CH_3$ and $–C(O)OCH_3$.

5. A compound, or a pharmaceutically acceptable salt thereof, selected from:

	
	
	

	
	
	
	
	

	
	
	
	

	
	
	
	
	

	
	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	
	
	
	

	

6. The compound of claim 4, or a pharmaceutically acceptable salt thereof, which is:



.

7. The compound of claim 3, or a pharmaceutically acceptable salt thereof, selected from:

	
	

	
	
	
	

8. The compound of claim 2, wherein R_3 is selected from $–CH_2CH_2R_{8b}$ and $-CR_{8a}=CR_{8a}R_{8b}$; wherein each R_{8a} is independently selected from hydrogen and C_{1-4}alkyl; and R_{8b} is selected from tetrazolyl, 1,3,4-oxadiazolyl, 4H-1,2,4-triazolyl, 5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl, 2-oxo-pyrimidinyl and imidazolyl; wherein said tetrazolyl, 1,3,4-oxadiazolyl, 4H-1,2,4-triazolyl, 2-oxo-pyrimidinyl or imidazolyl of R_{8b} is unsubstituted or substituted with 1 to 3 groups independently selected from C_{1-4}alkyl and C_{3-8}cycloalkyl.

9. A compound, or a pharmaceutically acceptable salt thereof, selected from:

	
	
	
	

	
	
	
	

	
	
	

10. The compound of claim 1 of formula Ib:



Ib

wherein:

n is selected from 0, 1 and 2;

m is selected from 0, 1 and 2;

Y_1 is selected from N and CR_7; wherein R_7 is selected from hydrogen and C_{1-4}alkyl;

R_1 is hydrogen;

R_2 is selected from hydrogen and halo;

R_3 is selected from $–CH_2CH_2R_{8b}$ and $–CR_{8a}=CR_{8a}R_{8b}$; wherein each R_{8a} is independently selected from hydrogen and C_{1-4}alkyl; and R_{8b} is selected from $–C(O)OR_{9a}$, $–C(O)NR_{9a}R_{9b}$, $–C(O)NHOR_{9a}$, $-C(O)X_2R_{9a}$, tetrazolyl, 1,3,4-oxadiazolyl, 4H-1,2,4-triazolyl, 5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl, 2-oxo-pyrimidinyl and imidazolyl; wherein X_2 is C_{1-4}alkylene; R_{9a} and R_{9b} are independently selected from hydrogen, C_{1-4}alkyl, hydroxy-substituted-C_{1-4}alkyl and halo-substituted-C_{1-4}alkyl; wherein said tetrazolyl, 1,3,4-oxadiazolyl, 4H-1,2,4-triazolyl, 2-oxo-pyrimidinyl or imidazolyl of R_{8b} is unsubstituted or substituted with a group selected from C_{1-4}alkyl and C_{3-8}cycloalkyl;

R_4 is selected from hydrogen and C_{1-4}alkyl; each

R_{5a} is independently selected from hydroxy, C_{1-4}alkyl, halo, nitro, cyano, halo-substituted-C_{1-4}alkyl, halo-substituted-C_{1-4}alkoxy, hydroxy-substituted-C_{1-4}alkyl, C_{1-4}alkoxy and $–C(O)R_{11a}$; wherein R_{11a} is selected from hydrogen and C_{1-4}alkyl; and

R_6 is C_{1-4}alkyl; or a pharmaceutically acceptable salt thereof.

11. The compound of claim 10, wherein R_3 is selected from $–CH_2CH_2R_{8b}$ and $-CR_{8a}=CR_{8a}R_{8b}$; wherein each R_{8a} is independently selected from hydrogen and C_{1-4}alkyl; and R_{8b} is selected from $–C(O)OR_{9a}$, $–C(O)NR_{9a}R_{9b}$, $–C(O)NHOR_{9a}$ and $-C(O)X_2R_{9a}$; wherein X_2 is C_{1-4}alkylene; R_{9a} and R_{9b} are independently selected from hydrogen, C_{1-4}alkyl, hydroxy-substituted-C_{1-4}alkyl and halo-substituted-C_{1-4}alkyl.

12. The compound of claim 11, or the pharmaceutically acceptable salts thereof, selected from:

	
	

13. A compound, or the pharmaceutically acceptable salt thereof, selected from:

	
	

	
	
	

14. A pharmaceutical composition comprising a compound of any one of claims 1 to 13 admixed with at least one pharmaceutically acceptable excipient.

15. The pharmaceutical composition of claim 14, wherein the excipient is selected from corn starch, potato starch, tapioca starch, starch paste, pre-gelatinized starch, sugars, gelatin, natural gums, synthetic gums, sodium alginate, alginic acid, tragacanth, guar gum, cellulose, ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethylcellulose, methyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, magnesium aluminum silicate, polyvinyl pyrrolidone, talc, calcium carbonate, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol,

agar-agar, sodium carbonate, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, clays, sodium stearate, calcium stearate, magnesium stearate, stearic acid, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, sodium lauryl sulfate, hydrogenated vegetable oil, peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, soybean oil, zinc stearate, sodium oleate, ethyl oleate, ethyl laureate, silica, and combinations thereof.

16. The pharmaceutical composition of claim 14 or 15, further comprising an additional therapeutic agent.

17. The pharmaceutical composition of claim 16, wherein the additional therapeutic agent is selected from an anticancer compound, an analgesic, an antiemetic, an antidepressant, and an anti-inflammatory agent.

18. Use of a compound according to any one of claims 1 to 13 in the manufacture of a medicament to treat cancer selected from breast, ovarian, endometrial, prostate, uterine, cervical and lung cancer.

19. Use of claim 18, wherein the medicament further comprises an additional therapeutic agent.

20. Use of claim 19, wherein the additional therapeutic agent is an anticancer drug, a pain medication, an antiemetic, an antidepressant or an anti-inflammatory agent.